the product in the database has an inactive status
indications:
Prevention of pulmonary complications in patients during intensive care after surgery.
Composition:
1 ampoule of 2 ml contains 15 mg of Ambroxol hydrochloride.
Action:
Mucolithic facilitating expectoration. It increases the secretion of mucus in the airways, stimulates the production of the pulmonary surfactant and improves the function of the ciliated epithelium of the respiratory system. As a result, the amount of mucus increases and improves its transport (mucociliary clearance), which makes it easier to cough up and relieves cough. Ambroxol binds approximately 90% of plasma proteins. The highest concentration of active substance was found in the lung tissue. CYP3A4 is the main isoenzyme responsible for the metabolism of ambroxol. In addition, ambroxol is mainly metabolised in the liver via a coupling mechanism. All these metabolites are excreted in 80-90% with urine. T0,5 is 10 hours.
Contraindications:
Hypersensitivity to the components of the preparation.
Precautions:
The preparation in the single recommended dose contains less than 1 mmol sodium (23 mg). Cases of severe skin lesions, such as Stevens-Johnson syndrome and Lyell syndrome, have been very rarely observed. In the event of new lesions within the skin or mucous membranes, it is necessary to prevent the ambroxol from being discontinued.
Pregnancy and lactation:
Caution should be exercised when used during pregnancy. Especially in the first trimester of pregnancy, ambroxol is not recommended. Ambroxol is excreted in human milk. The use of ambroxol in breast-feeding women is not recommended.
Adults: 1 amp. 2-3 times daily in a slow intravenous injection, in severe cases, a single dose of up to 2 amps can be increased. The solution may also be administered by drip infusion with 5% Glucose solution, 5% fructose solution, saline solution in water or with Ringer's solution.
(C)
